Adagio has pivotal VT data, FDA Breakthrough Device status, and a CE-Marked system, but no current revenue, a going-concern warning, and a cash runway that makes every regulatory milestone matter.
References
Sources used in this report
SEC APISEC submissions JSON2026-05-14 · Issuer identity, ticker, exchange, CIK, SIC, filer status, and filing recency.SEC APISEC companyfacts JSON2026-05-14 · XBRL cross-check for revenue, losses, cash, assets, liabilities, equity, and operating cash flow.SEC filingFY2025 Form 10-K2026-03-27 · Business model, ULTA technology, clinical history, financials, going concern, patents, competition, manufacturing, employees, and risks.SEC filingQ1 2026 Form 10-Q2026-05-12 · Latest quarter financials, cash runway, going concern, debt, shares, IDE expansion, and risk updates.Company release furnished to SECQ1 2026 results release2026-05-12 · Q1 results, FULCRUM-VT progress, expanded access cases, cash, and potential milestone-warrant proceeds.Company release furnished to SECFULCRUM-VT pivotal results release2026-04-27 · Six-month pivotal trial outcome metrics and PMA support context.Company release furnished to SECNext-generation vCLAS IDE expansion release2026-04-08 · FDA IDE expansion for the next-generation vCLAS Ultra sub-study.SEC governance filing2026 definitive proxy statement2026-04-30 · Board, independence, committee, annual meeting, and governance evidence.